| Title |
Inhaled protein/peptide-based therapies for respiratory disease
|
|---|---|
| Published in |
Molecular and Cellular Pediatrics, April 2016
|
| DOI | 10.1186/s40348-016-0044-8 |
| Pubmed ID | |
| Authors |
Robert C. Fellner, Shawn T. Terryah, Robert Tarran |
| Abstract |
Asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF) are all chronic pulmonary diseases, albeit with different etiologies, that are characterized by airflow limitation, chronic inflammation, and abnormal mucus production/rheology. Small synthetic molecule-based therapies are commonly prescribed for all three diseases. However, there has been increased interest in "biologicals" to treat these diseases. Biologicals typically constitute protein- or peptide-based therapies and are often more potent than small molecule-based drugs. In this review, we shall describe the pros and cons of several different biological-based therapies for respiratory disease, including dornase alfa, a recombinant DNAase that reduces mucus viscosity and short palate lung and nasal epithelial clone 1 (SPLUNC1)-derived peptides that treat Na(+) hyperabsorption and rebalance CF airway surface liquid homeostasis. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 98 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 98 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 18% |
| Student > Ph. D. Student | 16 | 16% |
| Student > Bachelor | 10 | 10% |
| Student > Master | 10 | 10% |
| Other | 6 | 6% |
| Other | 14 | 14% |
| Unknown | 24 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 16% |
| Biochemistry, Genetics and Molecular Biology | 13 | 13% |
| Chemistry | 10 | 10% |
| Medicine and Dentistry | 8 | 8% |
| Agricultural and Biological Sciences | 6 | 6% |
| Other | 20 | 20% |
| Unknown | 25 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2023.
All research outputs
#7,026,300
of 24,453,338 outputs
Outputs from Molecular and Cellular Pediatrics
#21
of 105 outputs
Outputs of similar age
#94,336
of 304,175 outputs
Outputs of similar age from Molecular and Cellular Pediatrics
#3
of 8 outputs
Altmetric has tracked 24,453,338 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,175 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.